RISUG男性避孕针研究进展  

Research progress of reversible inhibition of sperm under guidance male contraceptive needle

作　　者：刘晃 张欣宗 Liu Huang;Zhang Xinzong(NHC Key Laboratory of Male Reproduction and Genetics,Guangdong Provincial Reproductive Science Institute,Guangdong Provincial Fertility Hospital,Human Sperm Bank of Guangdong Province,Guangzhou 510060,China)

机构地区：[1]国家卫生健康委男性生殖与遗传重点实验室,广东省生殖科学研究所,广东省生殖医院,广东省人类精子库,广州510600

出　　处：《中华生殖与避孕杂志》2021年第8期712-716,共5页Chinese Journal of Reproduction and Contraception

基　　金：广东省自然科学基金(2021A1515011544);广东省医学科研基金项目(B2021453,A2021259);广东省计划生育科学技术研究所科创团队培育计划项目(C01)。

摘　　要：自1984年印度医学家报道“在指导下对精子的可逆性抑制”(reversible inhibition of sperm under guidance,RISUG)在男性避孕节育中有良好效果,并被宣布作为可以解放女性避孕痛苦的男性避孕药以来,国际上对RISUG的研究也有近40年时间。然而不同学者报道其研究结果差异甚大,部分学者报道该药效果不明显,部分报道其不良反应较大而无法深入研究。因此,该药物的有效性和安全性一直以来成为各家争论的焦点,其临床进展也缓慢不前,除药物效果值得推敲,其本身的安全性亦尚有待于进一步探讨和分析。本文就RISUG男性避孕针的研究背景、作用机理、实验基础、研究方法(包括给药方式、给药剂量、起效时间、作用效果、逆转方式、安全性等),以及所面临的问题和发展前景等方面作一综述。Since 1984,Indian medical experts reported that reversible inhibition of sperm under guidance(RISUG)had a good effect in male contraception,and was announced as a male contraceptive which could relieve female contraceptive pain,the international research on RISUG male contraceptive had been done nearly for 40 years.However,different studies had reported that the results were very different.Some scholars reported that the effect of the drug was not obvious,and some scholars reported that the side effects of the drug were too serious to be studied in depth.Therefore,the effectiveness and safety of the drug had always been the focus of debate,so its clinical progress was slow.In addition to the effect of the drug,its safety also needed to be further explored and analyzed.In this paper,the research background,action mechanism,experimental basis,research methods(including administration mode,administration and dose,onset time,action and effect,reversal mode and effect,safety evaluation,etc.),as well as the problems and development prospects of RISUG male contraceptive needle were reviewed.

关 键 词：可逆性精子抑制剂 避孕 男性 进展 

分 类 号：R169.41[医药卫生—公共卫生与预防医学]